Late-Stage Research

 
News Articles for Late-Stage Research top ^
New Investment Fund Will Advance Late-Stage Vaccines and other Global Health Technologies Canada NewsWire JPMorgan Chase, the Bill & Melinda Gates Foundation and partners announce successful capital raise for first-of-its-kind investment product NEW YORK , Sept.
Sign-up for New Investment Fund Will Advance Late-Stage Vaccines and other Global Health Technologies investment picks
2013/10/16
(This article was originally published earlier Wednesday.) By Joseph Walker An experimental drug being developed by Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SNY, SAN.FR) significantly reduced patients' cholesterol in a small late-stage study, one of a dozen clinical trials the company is conducting to gain regulatory approval for the treatment.
Sign-up for Regeneron and Sanofi's Cholesterol Drug Succeeds in Late-Stage Study investment picks
2014/1/8
Alkermes plc (NASDAQ: ALKS) today announced new developments related to its late-stage product candidates in its proprietary central nervous system (CNS) pipeline.
Sign-up for Alkermes Announces Advances With Its Late-Stage CNS Pipeline investment picks
By Russ Britt It was hard to tell the real winners from those riding market momentum Tuesday, but Bristol-Myers Squibb seemed to stand apart from the pack as the venerable drug maker hit a 52-week high after saying it was going ahead with one of its medications on late-stage tests for lung cancer.
Sign-up for Bristol-Myers Plans Late-Stage Tests on Yervoy as Lung-Cancer Treatment investment picks
2014/4/2
By Ed Ballard GlaxoSmithKline PLC (GSK) Tuesday said it had called a halt to a late-stage trial of a cancer vaccine.
Sign-up for GlaxoSmithKline Halts Late-Stage Trial of Cancer Vaccine investment picks
2014/1/28
DURHAM, N.C. and ALISO VIEJO, Calif.
Sign-up for bioMerieux's THxID®-BRAF Test for Detection of 2 BRAF Mutations V600E and V600K in Late-Stage Metastatic Melanoma adopted by Clarient, a GE Healthcare Company investment picks
2013/8/28
CAMBRIDGE, Mass., Aug.
Sign-up for Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer investment picks
2013/11/3
By Peter Loftus An experimental Merck & Co.
Sign-up for Merck's Experimental HPV Vaccine Shows Promise in Late Stage Trial investment picks
2013/12/9
Alkermes plc (NASDAQ: ALKS) today announced that data will be presented at the 52 nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec.
Sign-up for Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP Meeting investment picks
2014/1/13
Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments Investor conference call to be held today, January 13 at 8:30 AM EST/1:30 PM GMT DUBLIN , Jan.
Sign-up for Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness investment picks
2014/1/13
New Phase in Company Evolution from Genetics to Therapies THE WOODLANDS, Texas , Jan.
Sign-up for Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization investment picks
2014/3/3
http://media.marketwire.com/attachments/201210/52482_theravance_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1094777&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Late-Stage Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Late Trading  |  Next: Latest Report